Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 3/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 3/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 3/20 | 1.00 |
| ▸ | GRIK1 | P39086 | 2/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 2/20 | 1.00 |
| ▸ | GRIK3 | Q13003 | 2/20 | 1.00 |
| ▸ | GRIK4 | Q16099 | 2/20 | 1.00 |
| ▸ | GRIK5 | Q16478 | 2/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ym-90K SCHEMBL29798088 | 1.00 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL29384442 | 0.99 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL1055529 | 0.99 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL678466 | 0.99 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL5723322 | 0.85 | GRIA1 (0.73) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL5723327 | 0.85 | GRIA1 (0.73) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL14142767 | 0.83 | GRIK1 (0.70) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL13227266 | 0.83 | SLC22A6 (0.71) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8682439 | 0.81 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Water SCHEMBL8145177 | 0.81 | GRIK1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | claimed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | claimed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| CN-101990431-A | Methods and assays for detecting and treating hypoglycemia | UNIV MIAMI | 2011-03-23 | — | — | CN | claimed |
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| US-7247610-B2 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI | 2007-07-24 | — | — | US | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| US-20040053850-A1 | Treatment of demyelinating diseases | ENDOCRINZ LIMITED (NZ) | 2004-03-18 | — | — | US | claimed |
| EP-1359933-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | Neuronz Limited (NZ) | 2003-11-12 | — | — | EP | claimed |
| EP-0778023-B1 | Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. | WYETH CORP (US) | 2003-03-12 | — | — | EP | claimed |
| JP-2002539162-A | — | — | 2002-11-19 | — | — | JP | claimed |
| WO-2002030447-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030448-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| EP-1161238-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | Aventis Pharma S.A. (FR) | 2001-12-12 | — | — | EP | claimed |
| WO-2000054772-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | AVENTIS PHARMA S.A. (FR) | 2000-09-21 | — | — | WO | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| JP-8003161-A | — | — | None | — | — | JP | disclosed |
| JP-8003160-A | — | — | None | — | — | JP | disclosed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220265680-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2022-08-25 | — | — | US | disclosed |
| CN-114728012-A | Ganaxolone for the treatment of status epilepticus | 马瑞纳斯制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220202831-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2022-06-30 | — | — | US | disclosed |
| EP-4009982-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | Marinus Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11110100-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210186987-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021026124-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281541-A1 | USE IN BRAIN DEGENERATIVE DISEASES | BRINKMANN VOLKER (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8519006-B2 | Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-1871749-B1 | Selurampanel | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG | 2011-12-01 | — | — | US | disclosed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338492-A1 | Methods and compositions for the treatment of alzheimer | Universidad del Pais Vasco (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| CN-101990431-A | Methods and assays for detecting and treating hypoglycemia | UNIV MIAMI | 2011-03-23 | — | — | CN | disclosed |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2213285-A2 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-1713459-B1 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2177520-A1 | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-2164487-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | Eisai R&D Management Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | NAGATO SATOSHI | 2009-11-05 | — | — | US | disclosed |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | NAGATO SATOSHI | 2009-11-05 | — | — | US | disclosed |
| US-7563811-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-7563811-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| WO-2009054543-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR PARKINSON'S DISEASE AND MOVEMENT DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054544-A1 | AMPA RECEPTOR ANTAGONISTS FOR PARKINSON'S DISEASE AND MOVEMENT DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053041-A2 | 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009011411-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR NEUROPATHIC PAIN | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | WO | disclosed |
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008150509-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080139662-A1 | Such as 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | BRINKMANN VOLKER | 2008-06-12 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1829539-A2 | A method for treating tension-type headache | HEADEXPLORER ApS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-20070082873-A1 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia | NOVARTIS AG (CH) | 2007-04-12 | — | — | US | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1713459-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | Novartis AG (CH) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| EP-1682157-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005094797-A2 | USE OF AMPA-RECEPTOR ANTAGONISTS FOR TREATING DEMENTIA | NOVARTIS AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-6942963-B1 | Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005058295-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005049039-A1 | COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049042-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TINNITUS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049041-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049040-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005039593-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039594-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MYOPIA | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| EP-1015013-A4 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1015013-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998030229-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-07-16 | — | — | WO | disclosed |
| JP-H083160-A | METHOD FOR SEPARATING AND PURIFYING 6-(1-H-IMIDAZOL-1-YL)-7-NITRO-2,3-(1H,4H)-QUINOXALINEDIONE HYDROCHLORIDE OR SULFATE | NIPPON KAYAKU CO LTD | 1996-01-09 | — | — | JP | disclosed |
| JP-H083160-A | METHOD FOR SEPARATING AND PURIFYING 6-(1-H-IMIDAZOL-1-YL)-7-NITRO-2,3-(1H,4H)-QUINOXALINEDIONE HYDROCHLORIDE OR SULFATE | NIPPON KAYAKU CO LTD | 1996-01-09 | — | — | JP | disclosed |
| JP-H083161-A | METHOD FOR SEPARATING 6-(1-H-IMIDAZOL-1-YL)-7-NITRO-2,3(1H,4H)-QUINOXALINEDIONE | NIPPON KAYAKU CO LTD | 1996-01-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | GRIA1 18/4885GRIA2 21/4885GRIA3 16/4885 |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | GRIA1 70/4885GRIA2 101/4885GRIA3 90/4885 |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRIA1 905/4885GRIA2 510/4885GRIA3 198/4885 |
| US-20210186987-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20220265680-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20100256191-A1 | AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY | GRIK5, GABRE, GABRA5 | GRIA1 47/4885GRIA2 48/4885GRIA3 34/4885 |
| US-20100179193-A1 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain | CHRNA5, GRIN3A, CHRNA2 | GRIA1 70/4885GRIA2 69/4885GRIA3 60/4885 |
| US-11110100-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | GRIA1 20/4885GRIA2 21/4885GRIA3 18/4885 |
| US-20080139662-A1 | Such as 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | S1PR2, S1PR1, S1PR3 | GRIA1 312/4885GRIA2 149/4885GRIA3 317/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | GRIA1 513/4885GRIA2 519/4885GRIA3 804/4885 |
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | GRIA1 651/4885GRIA2 662/4885GRIA3 832/4885 |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | GRIA1 739/4885GRIA2 792/4885GRIA3 1030/4885 |
| US-20070082873-A1 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia | GABRE, GABRA2, GABRA3 | GRIA1 44/4885GRIA2 43/4885GRIA3 36/4885 |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | GRIA1 2085/4885GRIA2 2341/4885GRIA3 2201/4885 |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRIA1 22/4885GRIA2 21/4885GRIA3 18/4885 |
| US-20220202831-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | GRIK1, GRIK2, GRIK5 | GRIA1 20/4885GRIA2 48/4885GRIA3 28/4885 |
| US-20130281541-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | GRIA1 115/4885GRIA2 201/4885GRIA3 143/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | GRIA1 26/4885GRIA2 19/4885GRIA3 7/4885 |
| US-20100222354-A1 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain | AKR1B1, AKR1C1, AKR1C2 | GRIA1 24/4885GRIA2 63/4885GRIA3 56/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | GRIA1 26/4885GRIA2 33/4885GRIA3 28/4885 |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | GRIA1 131/4885GRIA2 127/4885GRIA3 108/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | GRIA1 651/4885GRIA2 662/4885GRIA3 832/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | GRIA1 115/4885GRIA2 201/4885GRIA3 143/4885 |
| US-20100297181-A1 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ | GRIK5, GRIK4, GRIK1 | GRIA1 34/4885GRIA2 40/4885GRIA3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.